- Conditions
- Mammography, Breast Cancer, Radiology
- Interventions
- Search only for masses, Search only for calcifications, Search for both together, Search for one after the other
- Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1537–1560
of 16,551
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sly Syndrome, MPS VII, Mucopolysaccharidosis, Mucopolysaccharidosis VII
- Interventions
- UX003
- Drug
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Industry
- Eligibility
- 5 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 4
- States / cities
- Oakland, California • Orange, California • Minneapolis, Minnesota + 1 more
- Conditions
- Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Acquired Lymphedema, Congenital Lymphedema
- Interventions
- Perforator Flap Breast Reconstruction, Vascularized Lymph Node Transfer
- Procedure
- Lead sponsor
- The National Institute of Lymphology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • New Orleans, Louisiana • Charleston, South Carolina
- Conditions
- Breast Cancer
- Interventions
- NeuVax vaccine, Trastuzumab, GM-CSF
- Biological · Drug
- Lead sponsor
- Cancer Insight, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 24
- States / cities
- Santa Monica, California • Santa Rosa, California • Washington D.C., District of Columbia + 18 more
- Conditions
- Systemic Lupus Erythematosus, Active Refractory Rheumatoid Arthritis
- Interventions
- Inebilizumab, Blinatumomab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 18
- States / cities
- Scottsdale, Arizona • Aurora, Colorado • Hialeah, Florida + 13 more
- Conditions
- Breast Cancer
- Interventions
- Polygenic Risk Score
- Genetic
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- X Linked Hypohidrotic Ectodermal Dysplasia
- Interventions
- Not listed
- Lead sponsor
- Edimer Pharmaceuticals
- Industry
- Eligibility
- 4 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Secukinumab
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 50 Years to 100 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 13
- States / cities
- Avondale, Arizona • Peoria, Arizona • Westlake Village, California + 9 more
- Conditions
- Breast Cancer
- Interventions
- Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography
- Device
- Lead sponsor
- U-Systems, Inc.
- Industry
- Eligibility
- 25 Years and older · Female only
- Enrollment
- 15,679 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Indio, California • Monterey, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Breast Cancer
- Interventions
- Doxorubicin and cyclophosphamide (AC) + bevacizumab, Docetaxel (T) + bevacizumab, Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab, Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab, Bevacizumab and trastuzumab maintenance therapy, Bevacizumab maintenance therapy
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 214 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 1
- States / cities
- Bridgewater, New Jersey
- Conditions
- Breast Cancer
- Interventions
- Contrast Enhanced Digital Mammography
- Device
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 461 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Erythropoietic Protoporphyria (EPP)
- Interventions
- MT-7117 low dose, MT-7117 high dose, Placebo
- Drug
- Lead sponsor
- Tanabe Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • San Francisco, California • Miami, Florida + 6 more
- Conditions
- Breast Cancer
- Interventions
- SRG-514
- Drug
- Lead sponsor
- SURGE Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 8
- States / cities
- Savannah, Georgia • Indianapolis, Indiana • Rochester, Minnesota + 5 more
- Conditions
- Acne
- Interventions
- clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Dupuytren's Contracture
- Interventions
- collagenase
- Drug
- Lead sponsor
- State University of New York
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2004
- U.S. locations
- 2
- States / cities
- Palo Alto, California • Stony Brook, New York
- Conditions
- Breast Cancer
- Interventions
- History and Physical Exam, Grip Strength Measurement, Surveys, Blood Collection, Ultrasound of Hand/Wrist
- Other · Behavioral · Procedure
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- GIST and CML
- Interventions
- imatinib mesylate
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Seborrheic Dermatitis
- Interventions
- Test Product 49778, Test Product 10156, Vehicle (placebo)
- Drug
- Lead sponsor
- Medicis Global Service Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 22
- States / cities
- Fremont, California • Los Angeles, California • San Diego, California + 19 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- RWJ-445380 100 mg, RWJ-445380 200 mg, RWJ-445380 300 mg, Placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 259 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 10 more
- Conditions
- Food Allergy, Asthma, Allergic Rhinitis, Atopic Dermatitis, Eosinophilic Esophagitis
- Interventions
- Not listed
- Lead sponsor
- Arkansas Children's Hospital Research Institute
- Other
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Tympanomastoid Surgery, Cochlear Implant, Mastoidectomy, Cholesteatoma
- Interventions
- 0.25% Bupivacaine + Clonidine
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Locally Advanced Malignant Neoplasm, Breast Cancer
- Interventions
- Propranolol, DOT imaging, Paclitaxel, Nab-paclitaxel, Trastuzumab, Pertuzumab, Doxorubicin, Cyclophosphamide, Surgery, Premedication, Anti-nausea therapy, Pegfilgrastim
- Drug · Other · Procedure
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Onychomycosis
- Interventions
- SUBA-itraconazole, Itraconazole, Placebo
- Drug
- Lead sponsor
- Halcygen Pharmaceuticals Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 8
- States / cities
- Altamonte Springs, Florida • Miami, Florida • Boise, Idaho + 5 more
- Conditions
- Breast Cancer, Early-stage Breast Cancer
- Interventions
- Stereotactic Ablative Breast Radiotherapy
- Radiation
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 50 Years and older · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Miami, Florida